Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
04 11 2021
Historique:
received: 16 08 2021
accepted: 04 10 2021
entrez: 5 11 2021
pubmed: 6 11 2021
medline: 24 12 2021
Statut: epublish

Résumé

Endocrine therapies for prostate cancer inhibit the androgen receptor (AR) transcription factor. In most cases, AR activity resumes during therapy and drives progression to castration-resistant prostate cancer (CRPC). However, therapy can also promote lineage plasticity and select for AR-independent phenotypes that are uniformly lethal. Here, we demonstrate the stem cell transcription factor Krüppel-like factor 5 (KLF5) is low or absent in prostate cancers prior to endocrine therapy, but induced in a subset of CRPC, including CRPC displaying lineage plasticity. KLF5 and AR physically interact on chromatin and drive opposing transcriptional programs, with KLF5 promoting cellular migration, anchorage-independent growth, and basal epithelial cell phenotypes. We identify ERBB2 as a point of transcriptional convergence displaying activation by KLF5 and repression by AR. ERBB2 inhibitors preferentially block KLF5-driven oncogenic phenotypes. These findings implicate KLF5 as an oncogene that can be upregulated in CRPC to oppose AR activities and promote lineage plasticity.

Identifiants

pubmed: 34737261
doi: 10.1038/s41467-021-26612-1
pii: 10.1038/s41467-021-26612-1
pmc: PMC8568894
doi:

Substances chimiques

AR protein, human 0
KLF5 protein, human 0
Kruppel-Like Transcription Factors 0
Receptors, Androgen 0
ERBB2 protein, human EC 2.7.10.1
Receptor, ErbB-2 EC 2.7.10.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

6377

Subventions

Organisme : NCI NIH HHS
ID : R01 CA229618
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA204856
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA174777
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA241486
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA212097
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA230617
Pays : United States

Informations de copyright

© 2021. The Author(s).

Références

Biochem J. 2009 Jan 1;417(1):313-22
pubmed: 18774944
Nat Commun. 2018 Jun 19;9(1):2404
pubmed: 29921838
Science. 2017 Jan 6;355(6320):84-88
pubmed: 28059768
Nucleic Acids Res. 2015 Jul 13;43(12):5880-97
pubmed: 25908785
Int J Cancer. 2006 Mar 15;118(6):1346-55
pubmed: 16184550
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Genes Cancer. 2012 Feb;3(2):102-16
pubmed: 23050043
Cell. 2015 May 21;161(5):1215-1228
pubmed: 26000489
Cancer Cell. 2017 Dec 11;32(6):792-806.e7
pubmed: 29153843
Cell. 2014 Sep 25;159(1):176-187
pubmed: 25201530
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Neoplasia. 2014 Nov 20;16(11):883-99
pubmed: 25425963
Cancer Cell. 2011 Oct 18;20(4):457-71
pubmed: 22014572
Nat Med. 2016 Apr;22(4):369-78
pubmed: 26928463
Nat Commun. 2020 Feb 21;11(1):997
pubmed: 32081850
Cancer Res. 2011 Mar 15;71(6):2108-17
pubmed: 21248069
Sci Transl Med. 2019 Jul 31;11(503):
pubmed: 31366581
Nucleic Acids Res. 2019 Jan 8;47(D1):D745-D751
pubmed: 30407521
PLoS One. 2016 Nov 30;11(11):e0166731
pubmed: 27902734
Nat Cell Biol. 2008 Mar;10(3):353-60
pubmed: 18264089
Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17492-7
pubmed: 24101480
Cancer Res. 1994 May 15;54(10):2577-81
pubmed: 8168083
Nucleic Acids Res. 2012 May;40(10):4288-97
pubmed: 22287627
Mol Endocrinol. 2009 Sep;23(9):1385-96
pubmed: 19460858
Clin Cancer Res. 2019 Dec 1;25(23):6916-6924
pubmed: 31363002
Cancer Discov. 2018 Jan;8(1):108-125
pubmed: 28963353
Cancer Cell. 2016 Oct 10;30(4):563-577
pubmed: 27728805
Cancer Cell. 2004 Nov;6(5):517-27
pubmed: 15542435
Nat Rev Cancer. 2015 Dec;15(12):701-11
pubmed: 26563462
Nucleic Acids Res. 2013 May 1;41(10):e108
pubmed: 23558742
Differentiation. 2008 Jul;76(6):682-98
pubmed: 18462434
Cancers (Basel). 2020 Mar 21;12(3):
pubmed: 32245249
Gut. 2015 May;64(5):707-19
pubmed: 25053715
Clin Cancer Res. 2006 Apr 15;12(8):2442-8
pubmed: 16638850
Cell Rep. 2015 Aug 11;12(6):922-36
pubmed: 26235627
Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436
pubmed: 31061129
Prostate. 2003 May 1;55(2):81-8
pubmed: 12661032
Nat Commun. 2021 Mar 17;12(1):1714
pubmed: 33731701
Cancer Res. 2012 Sep 1;72(17):4504-14
pubmed: 22745369
Nat Commun. 2019 Jan 17;10(1):278
pubmed: 30655535
Clin Cancer Res. 2016 Jul 15;22(14):3672-82
pubmed: 26936914
Nat Genet. 2016 Feb;48(2):176-82
pubmed: 26656844
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
J Clin Oncol. 2011 Sep 20;29(27):3651-8
pubmed: 21859989
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Gastroenterology. 2008 Jan;134(1):120-30
pubmed: 18054006
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Genome Biol. 2008;9(9):R137
pubmed: 18798982
Urol Oncol. 2013 Jan;31(1):82-6
pubmed: 21396844
Nat Med. 2016 Mar;22(3):298-305
pubmed: 26855148
Prostate. 2018 Sep;78(13):981-991
pubmed: 29790189
Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):644-9
pubmed: 26721396
Nucleic Acids Res. 2019 Jan 8;47(D1):D729-D735
pubmed: 30462313
Cell. 2015 Nov 5;163(4):1011-25
pubmed: 26544944
Cancer Discov. 2017 Jan;7(1):54-71
pubmed: 27784708
Cancer Res. 2006 Apr 1;66(7):3903-11
pubmed: 16585219
Differentiation. 2018 Sep - Oct;103:24-45
pubmed: 30224091
Cell Death Dis. 2020 Jun 16;11(6):466
pubmed: 32546700
Cancer Res. 2012 Jul 15;72(14):3457-62
pubmed: 22710436
Cell Rep. 2018 Dec 18;25(12):3530-3542.e5
pubmed: 30566875
Nat Methods. 2015 Apr;12(4):357-60
pubmed: 25751142
Cancer Res. 2017 Jul 1;77(13):3417-3430
pubmed: 28473532
Oncotarget. 2015 Apr 20;6(11):9086-98
pubmed: 25871401
Cancer Res. 2013 Jan 15;73(2):483-9
pubmed: 23117885
Genome Biol. 2014 Mar 03;15(3):R47
pubmed: 24580837
Endocr Relat Cancer. 2015 Dec;22(6):T187-97
pubmed: 26307022
Endocr Relat Cancer. 2020 Feb;27(2):R35-R50
pubmed: 31804971
Life Sci Alliance. 2018 Dec 28;2(1):e201800115
pubmed: 30620009

Auteurs

Meixia Che (M)

Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA.

Aashi Chaturvedi (A)

Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA.

Sarah A Munro (SA)

University of Minnesota Supercomputing Institute, University of Minnesota, Minneapolis, MN, 55455, USA.

Samuel P Pitzen (SP)

Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA.
Graduate Program in Molecular, Cellular, and Developmental Biology and Genetics, University of Minnesota, Minneapolis, MN, 55455, USA.

Alex Ling (A)

Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN, 55455, USA.

Weijie Zhang (W)

Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN, 55455, USA.

Josh Mentzer (J)

Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN, 55455, USA.

Sheng-Yu Ku (SY)

Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, 02215, USA.

Loredana Puca (L)

Division of Medical Oncology, Weill Cornell Medicine, New York, NY, 10065, USA.

Yanyun Zhu (Y)

Division on Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Andries M Bergman (AM)

Division on Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Tesa M Severson (TM)

Division on Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Colleen Forster (C)

Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, 55455, USA.

Yuzhen Liu (Y)

Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA.

Jacob Hildebrand (J)

Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA.
Graduate Program in Microbiology, Immunology, and Cancer Biology, University of Minnesota, Minneapolis, MN, 55455, USA.

Mark Daniel (M)

Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA.
Graduate Program in Microbiology, Immunology, and Cancer Biology, University of Minnesota, Minneapolis, MN, 55455, USA.

Ting-You Wang (TY)

The Hormel Institute, University of Minnesota, Austin, MN, 55912, USA.

Luke A Selth (LA)

Flinders Health and Medical Research Institute and Flinders Centre for Innovation in Cancer, Flinders University, Bedford Park, SA, Australia.
Dame Roma Mitchell Cancer Research Laboratories and Freemasons Foundation Centre for Men's Health, Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia.

Theresa Hickey (T)

Dame Roma Mitchell Cancer Research Laboratories and Freemasons Foundation Centre for Men's Health, Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia.

Amina Zoubeidi (A)

Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada.
Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada.

Martin Gleave (M)

Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada.
Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada.

Rohan Bareja (R)

Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, 10065, USA.

Andrea Sboner (A)

Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, 10065, USA.

Wayne Tilley (W)

Dame Roma Mitchell Cancer Research Laboratories and Freemasons Foundation Centre for Men's Health, Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia.

Jason S Carroll (JS)

Cancer Research UK, University of Cambridge, CB2 0RE, Cambridge, UK.

Winston Tan (W)

Department of Medicine, Mayo Clinic, Jacksonville, FL, 32224, USA.

Manish Kohli (M)

Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, 84112, USA.

Rendong Yang (R)

Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA.
The Hormel Institute, University of Minnesota, Austin, MN, 55912, USA.

Andrew C Hsieh (AC)

Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA.

Paari Murugan (P)

Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, 55455, USA.

Wilbert Zwart (W)

Division on Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Himisha Beltran (H)

Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, 02215, USA.

R Stephanie Huang (RS)

Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN, 55455, USA.

Scott M Dehm (SM)

Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA. dehm@umn.edu.
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, 55455, USA. dehm@umn.edu.
Department of Urology, University of Minnesota, Minneapolis, MN, 55455, USA. dehm@umn.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH